Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

This study is testing whether a combination of two checkpoint inhibitor immunotherapy drugs — given directly into liver tumors — can work as a first-line treatment for hepatocellular carcinoma (HCC), which is the most common form of liver cancer. Delivering the drugs directly into the tumor (called intratumoral injection) may boost the immune response with fewer side effects. **You may be eligible if...** - You are over 18 with liver cancer confirmed by biopsy or imaging - Your estimated survival is more than 3 months - Your liver function is adequate (Child-Pugh class A or B) - Your blood counts and organ function meet the required thresholds - You have at least one measurable tumor **You may NOT be eligible if...** - You have previously participated in another clinical trial for this condition - Your liver function is severely impaired (Child-Pugh class C) - You have active autoimmune disease or are on immunosuppressants - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.